Related references
Note: Only part of the references are listed.Cardiovascular effects of pharmacologic therapies for smoking cessation
Diana M. Sobieraj et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2013)
The α3β4*nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse
Kia J. Jackson et al.
NEUROPHARMACOLOGY (2013)
Molecular Mechanisms Underlying Behaviors Related to Nicotine Addiction
Marina R. Picciotto et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
Nicotinic Receptors in Addiction Pathways
Frances M. Leslie et al.
MOLECULAR PHARMACOLOGY (2013)
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties
Clare Stokes et al.
NEUROPHARMACOLOGY (2012)
AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats
Lawrence Toll et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Tobacco addiction and the dysregulation of brain stress systems
Adrie W. Bruijnzeel
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2012)
Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats
Adrie W. Bruijnzeel et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Chronic Sazetidine-A at Behaviorally Active Doses Does Not Increase Nicotinic Cholinergic Receptors in Rodent Brain
G. Patrick Hussmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Nicotine Persistently Activates Ventral Tegmental Area Dopaminergic Neurons via Nicotinic Acetylcholine Receptors Containing α4 and α6 Subunits
Liwang Liu et al.
MOLECULAR PHARMACOLOGY (2012)
Varenicline induces manic relapse in bipolar disorder
Natasha Knibbs et al.
GENERAL HOSPITAL PSYCHIATRY (2011)
A case of late-life onset mania during Varenicline assisted smoking cessation
Dimitry Francois et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)
Electrophysiological Perspectives on the Therapeutic Use of Nicotinic Acetylcholine Receptor Partial Agonists
Roger L. Papke et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake
Christie D. Fowler et al.
NATURE (2011)
Placebo-Controlled Trial of Cytisine for Smoking Cessation
Robert West et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Varenicline induced mania in a 51 year old patient without history of bipolar illness
Saira Hussain et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Historical and current perspective on tobacco use and nicotine addiction
John A. Dani et al.
TRENDS IN NEUROSCIENCES (2011)
Varenicline Withdrawal-Induced Delirium With Psychosis
Alison C. May et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
H. Rollema et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
Roger L. Papke et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Nicotine addiction and nicotinic receptors: lessons from genetically modified mice
Jean-Pierre Changeux
NATURE REVIEWS NEUROSCIENCE (2010)
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats
Grazyna Biala et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2010)
Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptors
Sharon R. Grady et al.
NEUROPHARMACOLOGY (2010)
Neurocircuitry of Addiction
George F. Koob et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Hallucinations in the Context of Varenicline Withdrawal
Pekka Laine et al.
AMERICAN JOURNAL OF PSYCHIATRY (2009)
Corticotropin-Releasing Factor-1 Receptor Activation Mediates Nicotine Withdrawal-Induced Deficit in Brain Reward Function and Stress-Induced Relapse
Adrie W. Bruijnzeel et al.
BIOLOGICAL PSYCHIATRY (2009)
Varenicline-Induced Mania in a Bipolar Patient
Fadi Alhatem et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Cytisine-Based Nicotinic Partial Agonists as Novel Antidepressant Compounds
Yann S. Mineur et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of α4β2 nicotinic receptors in rats
Krista Spiller et al.
NEUROPHARMACOLOGY (2009)
NMDA Receptors Regulate Nicotine-Enhanced Brain Reward Function and Intravenous Nicotine Self-Administration: Role of the Ventral Tegmental Area and Central Nucleus of the Amygdala
Paul J. Kenny et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Corticotropin-Releasing Factor Within the Central Nucleus of the Amygdala and the Nucleus Accumbens Shell Mediates the Negative Affective State of Nicotine Withdrawal in Rats
Catherine A. Marcinkiewcz et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats
Mark G. LeSage et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2009)
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers
S. L. McColl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats
Adrie W. Bruijnzeel et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors
Karla B. Mihalak et al.
MOLECULAR PHARMACOLOGY (2006)
Cytisine for smoking cessation - A literature review and a meta-analysis
Jean-Francois Etter
ARCHIVES OF INTERNAL MEDICINE (2006)
Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
Douglas E. Jorenby et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Metabolism and disposition of varenicline, a selective alpha 4 beta 2 acetylcholine receptor partial agonist, in vivo and in vitro
RS Obach et al.
DRUG METABOLISM AND DISPOSITION (2006)
Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation
JW Coe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Nicotine induces conditioned place preferences over a large range of doses in rats
B Le Foll et al.
PSYCHOPHARMACOLOGY (2005)
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice
O Salminen et al.
MOLECULAR PHARMACOLOGY (2004)
Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change
JC Pruessner et al.
PSYCHONEUROENDOCRINOLOGY (2003)
Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents
JF Cryan et al.
BIOLOGICAL PSYCHIATRY (2003)
Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation
D Debruyne et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
A 'crash' course on psychostimulant withdrawal as a model of depression
AM Barr et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography
DC Perry et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Nicotine potentiation of brain stimulation reward reversed by DHβE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats
AA Harrison et al.
PSYCHOPHARMACOLOGY (2002)
Share Paper
